35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Inflammation, Oral Pain and Pharyngeal Discomfort (HA35-CHEW)

November 11, 2026 updated by: Nakhia Impex LLC

Prospective Single-Arm Open-Label Clinical Study of 35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Pain, Periodontal Inflammation, Gingival Recession and Pharyngeal Itch-Pain

To explore efficacy and safety of 35-kDa hyaluronan fragment (HA35) chewable tablets for relief of tooth-gingival pain, periodontal gingival inflammation, mild gingival recession, and pharyngeal itching-pain. Participants chew six tablets per dose, three times daily for 28 consecutive days. Assess subjective oral-pharyngeal symptoms, gingival inflammation, estimated gingival regrowth and safety events.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This is prospective, single-arm, open-label pilot clinical study. Eligible adult participants with periodontal condition, mild gingival recession and oral-gingival pain or pharyngeal discomfort receive HA35 chewable tablets. Each tablet weighs 600 mg containing 300 mg 35-kDa hyaluronan fragment. Subjects chew six tablets each administration (3 tablets on each molar side), three times daily for total 18 tablets/day (5.4 g HA35/day), for 28 consecutive days. Tablets dissolve by saliva in oral cavity after chewing. Evaluations are performed at baseline; 3 minutes post-first dose; 30 minutes post-first dose; Day 1, Day 7, Day 21, Day 28. Investigator assess gingival redness/swelling, exposed root length for estimated gingival regrowth. Subject self-report pain, itch-pain of throat. Exploratory facial-tissue related assessments are performed at Day 28. Adverse events are monitored throughout whole 28-day study period. Target enrollment: 30 adult participants.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shandong
      • Qingdao, Shandong, China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18-75 years old, male or female adult.
  2. Clinical findings of periodontal disease with mild gingival recession; with at least one of following: chronic gingival/tooth-root pain; pain after dental procedure (restoration, scaling, extraction, transplantation etc.); subjective pharyngeal itching or pharyngeal pain.
  3. Able to independently complete NRS scale self-assessment.
  4. Able to follow full 28-days three-times-daily chewable-tablet protocol.
  5. Voluntarily sign written informed-consent document.

Exclusion Criteria:

  1. Severe periodontal disease requiring immediate surgical intervention; active oral ulcer, oral malignant lesion.
  2. Pregnant or lactating women.
  3. Known hypersensitivity / allergy to hyaluronan / sodium hyaluronate or tablet excipients.
  4. Severe gastrointestinal diseases.
  5. Simultaneous participation in other oral-pharyngeal-related clinical trials.
  6. Psychiatric disorders that compromise study compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HA35 Chewable Tablets

Intervention description: Each tablet 600 mg containing 300 mg HA35. Chew six tablets per dose (3 each side molars), three times daily, total 18 tablets/day (5.4 g HA35/day), 28 consecutive days. Tablets dissolve in saliva after chewing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary Outcome Measures
Time Frame: Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28

Participant-reported 0-10 numerical rating scale for tooth and gingival pain; 0=no pain,10=worst imaginable pain

Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
Pharyngeal Itching-Pain NRS Score
Time Frame: Baseline,30 minutes after first administration, Day-1, Day-7, Day-28

Participant-reported 0-10 NRS for throat itching and pain;0=no symptom, 10=worst imaginable itch-pain

Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
Gingival Inflammatory Redness-Swelling NRS Score
Time Frame: Baseline, Day-1, Day-7, Day-21, Day-28

Investigator-rated composite 0-10 score of gingival redness and swelling;0=no inflammation;10=severe gingival redness and swelling

Baseline, Day-1, Day-7, Day-21, Day-28

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Estimated Gingival Regrowth Length (mm)
Time Frame: Baseline, Day-21, Day-28

Investigator measurement of exposed tooth-root length using 1-mm precision ruler; calculate estimated gingival regrowth from baseline

Baseline, Day-21, Day-28
Exploratory Facial-tissue Reduction Score
Time Frame: Baseline, Day-28

Investigator visual-tactile 0-10 rating scale (exploratory only): reduction of facial roundness, forehead-skin thickness, eyelid thickness, double-chin prominence;0=no reduction;10=maximum reduction. Exploratory endpoint only

Baseline, Day-28
Participant Overall Satisfaction Score
Time Frame: Day-28 end-of-treatment

Participant self-reported overall satisfaction 0-10 scale for oral-pharyngeal improvement. 0=most dissatisfied, 10=most satisfied

Day-28 end-of-treatment
Adverse Event Incidence
Time Frame: Entire 28-day study period

Incidence of product-related adverse events including oral mucosal irritation, hypersensitivity, gastrointestinal discomfort, throat irritation

Entire 28-day study period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 15, 2026

Primary Completion (Estimated)

January 12, 2027

Study Completion (Estimated)

January 19, 2027

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HA35202612

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.